# CARES-009 (NCT04521153)

> Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04521153
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Shanghai Zhongshan Hospital
- Conditions: Hepatocellular Carcinoma; Immunotherapy; Molecular Targeted Therapy
- Interventions: Camrelizumab; Apatinib Mesylate; Radical surgery
- Enrollment: 294
- Primary outcome: Event-free survival (EFS) assessed by investigator
- Primary outcome: The rate of subjects of major pathological response (MPR)

## Indexed commentary on CARES-009 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 17
- YouTube: 3
- Podcasts: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cares-009-nct04521153

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04521153", "email": "<work email>"}; the inbox owner confirms by the emailed link.